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A commentary on
Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential
applications for vaccine development
by Rella, A., Mor, V., Farnoud, A. M., Singh, A., Shamseddine, A. A., Ivanova, E., et al. (2015). Front.
Microbiol. 6:836. doi: 10.3389/fmicb.2015.00836
Cryptococcosis is an opportunistic fungal infection associated with AIDS. Differences in the
clinical manifestations of cryptococcosis have been observed among encapsulated Cryptococcus
species, with neoformans strainsmostly isolated from individuals with impaired immunity (Dromer
et al., 1994) and gattii strains from immunocompetent hosts (Speed and Dunt, 1995). This
medically important fungus is globally distributed resulting in clinical disease in approximately
30% of HIV infected individuals mainly in areas such as South East Asia and sub-Saharan Africa
(Powderly, 1993). Cryptococcossis is acquired after airborne fungi in the form of desiccated or
poorly encapsulated yeast cells or as basidiospores enter the host by inhalation (Neilson et al.,
1977; Levitz, 1991) resulting in asymptomatic disease or dormant infections. Progression toward
pulmonary and systemic disease commonly occurs in individuals with severely compromised
immune responses. There are 1 million cases of cryptococcal meningitis each year worldwide,
resulting in approximately 600,000 deaths (Park et al., 2009).
C. neoformans infection presents formidable problems for the host immune response, including
the presence of titan cells in tissue (Zaragoza and Nielsen, 2013), a lack of antibody responsiveness
to capsular polysaccharide, and extensive accumulation of polysaccharide in tissue (Goldman
et al., 1995). The presence of glucuronoxylomannan (GXM), the main capsular polysaccharide of
C. neoformans, in tissue seems to be the most important contributor to the fungus pathogenesis
given that the capsule is abundantly shed during infection and has been associated with
immunosuppressive effects (Vecchiarelli, 2000), including an increase in HIV load (Pettoello-
Mantovani et al., 1992) and cellular infectivity (Pettoello-Mantovani et al., 1994).
Despite its clinical relevance, there is no vaccine available for cryptococcosis. Several initiatives
to generate artificial active immunity to prevent patients from developing this disease have been
attempted including the development of a GXM bound to tetanus toxoid (Devi et al., 1991), a
genetically engineered murine IFN-γ -producing cryptococcal strain (Wormley et al., 2007), and
fungal components (Chaturvedi et al., 2014). Also, passive administration of antibodies has shown
encouraging results in the laboratory (Casadevall et al., 1998). Nonetheless, although important
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insights have been acquired to better understand cryptococcosis,
none of these initiatives have reached translational fruition. Thus,
the development of alternative vaccination approaches is urgently
needed.
Studies in mice with cell-mediated immunity deficiency
support the importance of T-cells during cryptococcal infection
given that these animals fail to mount T-dependent antibody
responses (Graybill and Drutz, 1978; Cauley and Murphy, 1979).
Conversely, thymus transplantation in these mice followed by
fungal infection significantly prolongs survival (Graybill et al.,
1979). Another piece of evidence supporting the role of T-cells
in cryptococcal infection is that transference of T-cells frommice
with cryptococcosis confers immunity to recipient mice (Lim and
Murphy, 1980). In fact, the general consensus among medical
mycologists is that it would be challenging to develop of an
effective and protective anti-cryptococcal vaccine in individuals
with impaired CD4+ T cell immunity, particularly in AIDS
patients.
Rella et al., introduces a promising and innovative vaccination
strategy to prevent cryptococcosis, by demonstrating
that accumulation of sterylglucosides (SGs), a class of
immunomodulatory glycolipids, in a genetically engineered
non-pathogenic C. neoformans (1sgl1) strain that lacks the
sterylglucosidase enzyme and administered to mice preceding
fungal infection confers complete protection in animals
challenged with lethal doses of either C. neoformans or C. gattii
(Rella et al., 2015). Rodents immunized with the 1sgl1 strain a
month prior to infection with wild-type cryptococci survived
significantly longer than unexposed mice. Surprisingly, the1sgl1
strain induces a CD4+ T cells independent immunity since
previous immunization to infection of immunocompromised
mice completely protected these animals against cryptococcosis.
SGs immune stimulation suggests the possibility that prevention
and sustained protection may be achievable in the context of
T cell deficiency possibly by other immune mechanisms. For
instance, CD8+ T cells may compensate for the loss of CD4+
T cells to facilitate protection against cryptococcosis in an
IFN-γ-dependent manner (Lindell et al., 2005).
B cells play a critical role in protection against experimental
cryptococcosis (Subramaniam et al., 2010; Szymczak et al., 2013).
T cell independent immune responses result in the activation
of B cells and the production of immunoglobulinM (IgM)
which may be stimulated by SGs. For example, B-cell-deficient
mice are susceptible to cryptococcal lung infection (Rivera
et al., 2005), indicating an association between B cells and
pulmonary inflammation control. In mice, IgM deficiency is
linked with increased vulnerability to C. neoformans pulmonary
infection and reduced phagocytosis, which can be restored by
administration of IgM (Subramaniam et al., 2010). B cells from
C. neoformans infected rodents produce fungal binding IgM and
depletion of these cells resulted in impairedmacrophage function
facilitating cryptococcal dissemination to the brain (Rohatgi and
Pirofski, 2012). Therefore, B cells might be SGs-glycolipid targets
given that these humoral regulators enhance innate antifungal
immunity via natural IgM, which promotes fungal containment
in the lungs.
SGs have been shown to modulate cytokine production (Lee
et al., 2007) suggesting their plausible implication in natural
killer T (NKT) cell activation and macrophage polarization,
innate immune responses that may be efficacious in prevention
or treatment of cryptococcosis. NKT cells play an important
role in the development of Th1 responses and host resistance
to C. neoformans. For instance, NKT cells are increased in
the lungs of mice infected with C. neoformans, associating
the chemokine MCP-1 in their recruitment and accumulation
(Kawakami et al., 2001a). Interestingly, glycolipid-activation
of NKT cells increases IFN-γ levels and fungal clearance
suggesting another possible target cell for stimulation by
the 1sgl1 strain (Kawakami et al., 2001b). NKT cells also
secrete IL-4, suggesting that this subset regulates both Th1- and
Th2-polarization (Taniguchi et al., 2003). Likewise, the host
response to C. neoformans in the lungs correlates with
macrophage polarization (Davis et al., 2013), whereby M1
(classically activated)macrophages lead to Th1 responses (mainly
IFN-γ dominated) and M2 (alternatively activated) macrophages
lead to Th2 responses. M1 macrophages kill cryptococci more
effectively than M2 macrophages suggesting that SGs-mediated
changes in the cytokine environment can influence macrophage
polarization, with M1 macrophages augmenting host defense
against C. neoformans.
Further studies focusing on the immune responses generated
by SGs and safety issues associated with delivering live-attenuated
cryptococci, heat-killed fungi, or vesicle formulations containing
SGs preparations are necessary. However, these findings are
significant in the setting of HIV/AIDS immune deficiency
suggesting that the 1sgl1 strain might provide a potential
vaccination strategy against cryptococcosis. Rella et al., provide
a proof of concept study that opens a novel area of research
and a potential therapeutic strategy to prevent and reduce the
devastating consequences of cryptococcosis.
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